Celularity Stock Slides After CMS Withdraws Skin Substitute Reimbursement
Celularity’s stock drops after CMS pulls reimbursement for its LCD skin‑substitute, but the company’s diversified cell‑therapy pipeline and payer‑engagement strategy aim to offset the loss and drive future revenue growth.
3 minutes to read